{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:49:25Z","timestamp":1790290165884,"version":"4.1.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","seminarsinnephrology.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.semnephrol.2016.08.001","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T17:05:27Z","timestamp":1481735127000},"page":"436-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Developing Treatments for Chronic Kidney Disease in the 21st Century"],"prefix":"10.1016","volume":"36","author":[{"given":"Matthew D.","family":"Breyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2016.08.001_bib1","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2015.12.014","article-title":"US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"67","author":"Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib2","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1053\/j.ajkd.2015.12.015","article-title":"US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"67","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2215\/CJN.11261114","article-title":"Patient characteristics and outcomes by GN subtype in ESRD","volume":"10","author":"O\u2019Shaughnessy","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib4","doi-asserted-by":"crossref","first-page":"e110535","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ki.2015.230","article-title":"A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010","volume":"88","author":"Mills","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.ajkd.2013.10.043","article-title":"The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov","volume":"63","author":"Inrig","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2215\/CJN.00500115","article-title":"Optimizing enrollment of patients into nephrology research studies","volume":"11","author":"Selewski","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR decline as an end point in trials of CKD: a viewpoint from the FDA","volume":"64","author":"Thompson","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrneph.2012.43","article-title":"Proteinuria as a surrogate end point --- more data are needed","volume":"8","author":"Thompson","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s11892-009-0075-9","article-title":"The growing economic burden of diabetic kidney disease","volume":"9","author":"Foley","year":"2009","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib13","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.2337\/dc12-0669","article-title":"Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth","volume":"35","author":"Imperatore","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1464-5491.2004.01390.x","article-title":"Unchanged incidence of diabetic nephropathy in type 1 diabetes: a nation-wide study in Iceland","volume":"22","author":"Tryggvason","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/dmrr.2574","article-title":"The risk for diabetic nephropathy is low in young adults in a 17-year follow-up from the Diabetes Incidence Study in Sweden (DISS). Older age and higher BMI at diabetes onset can be important risk factors","volume":"31","author":"Svensson","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11892-015-0610-9","article-title":"Genetics of diabetic nephropathy: a long road of discovery","volume":"15","author":"McKnight","year":"2015","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib17","doi-asserted-by":"crossref","first-page":"e1002921","DOI":"10.1371\/journal.pgen.1002921","article-title":"New susceptibility loci associated with kidney disease in type 1 diabetes","volume":"8","author":"Sandholm","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib18","doi-asserted-by":"crossref","first-page":"e1005352","DOI":"10.1371\/journal.pgen.1005352","article-title":"Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: Family Investigation of Nephropathy and Diabetes (FIND)","volume":"11","author":"Iyengar","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib19","doi-asserted-by":"crossref","first-page":"e81888","DOI":"10.1371\/journal.pone.0081888","article-title":"A genome-wide search for linkage of estimated glomerular filtration rate (eGFR) in the Family Investigation of Nephropathy and Diabetes (FIND)","volume":"8","author":"Thameem","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000064500.89551.76","article-title":"Overview of glucose signaling in mesangial cells in diabetic nephropathy","volume":"14","author":"Haneda","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ki.2012.234","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy","volume":"82","author":"Weil","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2337\/diabetes.52.4.1023","article-title":"Nephrin expression is reduced in human diabetic nephropathy","volume":"52","author":"Doublier","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib23","doi-asserted-by":"crossref","first-page":"F956","DOI":"10.1152\/ajprenal.00532.2014","article-title":"A microscopic view on the renal endothelial glycocalyx","volume":"308","author":"Dane","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2337\/diabetes.55.04.06.db05-1619","article-title":"Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes","volume":"55","author":"Nieuwdorp","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib25","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib26","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/ndt\/13.10.2547","article-title":"Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group","volume":"13","author":"Schwartz","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib27","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s001250050616","article-title":"Patterns of renal injury in NIDDM patients with microalbuminuria","volume":"39","author":"Fioretto","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib29","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib30","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/eurheartj\/ehr017","article-title":"Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials","volume":"32","author":"Holtkamp","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db11-1667","article-title":"Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli","volume":"62","author":"Hodgin","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib33","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1681\/ASN.2014010028","article-title":"Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD","volume":"26","author":"Ledo","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0344-0338(11)80780-6","article-title":"The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis","volume":"187","author":"Bohle","year":"1991","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib36","doi-asserted-by":"crossref","first-page":"948417","DOI":"10.1155\/2015\/948417","article-title":"Inflammatory cytokines in diabetic nephropathy","volume":"2015","author":"Donate-Correa","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib37","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.02510213","article-title":"The modern spectrum of renal biopsy findings in patients with diabetes","volume":"8","author":"Sharma","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrneph.2010.58","article-title":"The RAAS in the pathogenesis and treatment of diabetic nephropathy","volume":"6","author":"Ruggenenti","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib42","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib43","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1073\/pnas.82.17.5963","article-title":"Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy","volume":"82","author":"Zatz","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib44","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib46","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib47","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib49","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib51","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib53","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib54","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib55","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib57","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib58","doi-asserted-by":"crossref","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib59","unstructured":"Janssen. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE). NCT02065791. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02065791; 2015 [accessed 03.24.15] (8)."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib60","unstructured":"AbbVie. Study Of Diabetic Nephropathy With Atrasentan (SONAR). NCT01858532. https:\/\/clinicaltrials.gov\/show\/NCT01858532; 2015 [accessed 02.14.2015]"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib61","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib62","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib63","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib64","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib66","article-title":"Renal efficacy and safety of anti-TGF-\u03b21 therapy in patients with diabetic nephropathy","author":"Voelker","year":"2014","journal-title":"Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib67","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2215\/CJN.11511114","article-title":"Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view","volume":"10","author":"Lambers Heerspink","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib68","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.10681014","article-title":"Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view","volume":"10","author":"Fried","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib69","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/ndt\/gfn644","article-title":"Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients","volume":"24","author":"Vogt","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib70","doi-asserted-by":"crossref","first-page":"e1362","DOI":"10.1097\/MD.0000000000001362","article-title":"Increased risk of end-stage renal disease (ESRD) requiring chronic dialysis is associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs): nationwide case-crossover study","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib71","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib72","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)70270-1","article-title":"Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study","volume":"365","author":"Graham","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2261-12-93","article-title":"Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension","volume":"12","author":"Aljadhey","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib74","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJM197812142992415","article-title":"Treatment of diabetic necrobiosis with aspirin or dipyridamole","volume":"299","author":"Sherwin","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib75","doi-asserted-by":"crossref","unstructured":"Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis. 2913;62:403-441.","DOI":"10.1053\/j.ajkd.2013.06.002"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib76","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1681\/ASN.2008070786","article-title":"Role of rituximab therapy in glomerulonephritis","volume":"21","author":"Jayne","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib77","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0344-0338(89)80058-5","article-title":"The pathogenesis of chronic renal failure","volume":"185","author":"Bohle","year":"1989","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib78","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2013080906","article-title":"Integrative biology identifies shared transcriptional networks in CKD","volume":"25","author":"Martini","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib79","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/db08-1328","article-title":"Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy","volume":"58","author":"Berthier","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib80","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00281-007-0090-3","article-title":"Complement in glomerular injury","volume":"29","author":"Berger","year":"2007","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib81","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2215\/CJN.06230614","article-title":"Molecules great and small: the complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib82","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotech"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib83","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib84","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrendo.2009.266","article-title":"Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily","volume":"6","author":"Flyvbjerg","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib85","doi-asserted-by":"crossref","first-page":"e0119699","DOI":"10.1371\/journal.pone.0119699","article-title":"Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes","volume":"10","author":"Guan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib86","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/prca.200900169","article-title":"Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis","volume":"4","author":"Hansen","year":"2010","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib87","doi-asserted-by":"crossref","first-page":"e113639","DOI":"10.1371\/journal.pone.0113639","article-title":"C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-\u03b2\/smad3 and IKB\u03b1 pathway","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib88","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib89","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib90","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib91","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib92","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.1001782","article-title":"The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction","volume":"185","author":"Thacker","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib93","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1681\/ASN.2006101125","article-title":"Mouse podocyte complement factor H: the functional analog to human complement receptor 1","volume":"18","author":"Alexander","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib94","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u05f3Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib95","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.immuni.2010.05.003","article-title":"Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis","volume":"32","author":"Durant","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib96","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1060028013512790","article-title":"Tofacitinib: the first janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis","volume":"47","author":"Vyas","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib97","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2353\/ajpath.2010.090268","article-title":"Human nephrosclerosis triggers a hypoxia-related glomerulopathy","volume":"176","author":"Neusser","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib98","doi-asserted-by":"crossref","first-page":"F653","DOI":"10.1152\/ajprenal.00163.2003","article-title":"Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli","volume":"286","author":"Banes","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib99","doi-asserted-by":"crossref","first-page":"F762","DOI":"10.1152\/ajprenal.00181.2005","article-title":"Role of the JAK\/STAT signaling pathway in diabetic nephropathy","volume":"290","author":"Marrero","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib100","unstructured":"Tuttle KR, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Liu J, et al. Baricitinib in diabetic kidney disease: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study. Paper presented at: 75th annual meeting of the American Diabetes Association, June 6, 2015, Boston, MA: 114-LB; 2015."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib101","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1084\/jem.169.4.1485","article-title":"Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line","volume":"169","author":"Matsushima","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib102","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib103","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4049\/jimmunol.161.2.805","article-title":"The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor","volume":"161","author":"Mellado","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib104","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1046\/j.1523-1755.2000.00311.x","article-title":"Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy","volume":"58","author":"Wada","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib105","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.ki.5000212","article-title":"The relationship between albuminuria, MCP-1\/CCL2, and interstitial macrophages in chronic kidney disease","volume":"69","author":"Eardley","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib106","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.V76906","article-title":"Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment","volume":"7","author":"Grandaliano","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib107","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jdiacomp.2012.06.006","article-title":"Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy","volume":"26","author":"Titan","year":"2012","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib108","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfs555","article-title":"Blockade of CCL2\/CCR2 signalling ameliorates diabetic nephropathy in db\/db mice","volume":"28","author":"Seok","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib109","doi-asserted-by":"crossref","first-page":"F1358","DOI":"10.1152\/ajprenal.00332.2011","article-title":"Monocyte\/macrophage chemokine receptor CCR2 mediates diabetic renal injury","volume":"301","author":"Awad","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib110","unstructured":"ChemoCentryx. A study to evaluate the safety and efficacy of CCX140-B in subjects with diabetic nephropathy. NCT01447147; 2014. https:\/\/clinicaltrials.gov\/show\/NCT01447147 [accessed 03.08.15]"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib111","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib112","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1084\/jem.178.6.2255","article-title":"Induction and function of vascular adhesion protein-1 at sites of inflammation","volume":"178","author":"Salmi","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib113","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1084\/jem.188.1.17","article-title":"Cloning of \u2009vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule","volume":"188","author":"Smith","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib114","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2003-09-3275","article-title":"Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1)","volume":"103","author":"Koskinen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib115","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00281-014-0417-9","article-title":"Ectoenzymes in leukocyte migration and their therapeutic potential","volume":"36","author":"Salmi","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib116","unstructured":"Astellas. A study to evaluate ASP8232 as add-on therapy to angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (ALBUM), NCT02358096. https:\/\/clinicaltrials.gov\/show\/NCT01447147 [accessed 03.08.15]."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib117","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1210\/me.2005-0241","article-title":"Insulin-like growth factor-I signaling in smooth muscle cells is regulated by ligand binding to the 177CYDMKTTC184 sequence of the \u03b23-subunit of \u03b1V\u03b23","volume":"20","author":"Maile","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib118","doi-asserted-by":"crossref","first-page":"18ra11","DOI":"10.1126\/scitranslmed.3000476","article-title":"A monoclonal antibody against \u03b1V\u03b23 integrin inhibits development of atherosclerotic lesions in diabetic pigs","volume":"2","author":"Maile","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib119","unstructured":"VascularPharmaceuticals. Phase 2 study to evaluate safety & efficacy of VPI-2690B in diabetic nephropathy patients. NCT02251067. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02251067 [accessed 08.22.15]."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib120","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1074\/jbc.M609146200","article-title":"Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling","volume":"282","author":"Zhao","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib121","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/sj.onc.1202975","article-title":"Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1)","volume":"18","author":"Hoeflich","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib122","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1126\/science.275.5296.90","article-title":"Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK\/JNK and p38 signaling pathways","volume":"275","author":"Ichijo","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib123","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/db15-0384","article-title":"ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice","volume":"64","author":"Tesch","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib124","unstructured":"Gilead. Efficacy, safety, and tolerability of GS-4997 in participants with diabetic kidney disease NCT02177786. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02177786; 2015 [accessed 07.29.15]."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib125","first-page":"29","article-title":"Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease","volume":"129","author":"Lin","year":"2015","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib126","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib127","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.2010.39","article-title":"Relation between kidney function, proteinuria, and adverse outcomes","volume":"303","author":"Hemmelgarn","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib128","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1681\/ASN.2004080632","article-title":"Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study","volume":"16","author":"Zhang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib129","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1681\/ASN.2008070730","article-title":"and albuminuria to classify CKD improves prediction of ESRD","volume":"20","author":"Hallan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib131","first-page":"382","article-title":"Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet","volume":"3","author":"Porrini","year":"2015","journal-title":"Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib132","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/j.ajkd.2008.05.026","article-title":"CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP)","volume":"52","author":"Saab","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib133","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/imj.12797","article-title":"Cost to government and society of chronic kidney disease stage 1-5: a national cohort study","volume":"45","author":"Wyld","year":"2015","journal-title":"Intern Med J"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2016.08.001_bib134","doi-asserted-by":"crossref","first-page":"iii73","DOI":"10.1093\/ndt\/gfs269","article-title":"Estimating the financial cost of chronic kidney disease to the NHS in England","volume":"27","author":"Kerr","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib135","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3111\/13696998.2014.979292","article-title":"Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US","volume":"18","author":"Slabaugh","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib136","series-title":"USRDS annual data report: epidemiology of kidney disease in the United States","year":"2013"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib137","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/2047487315598709","article-title":"Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers","volume":"23","author":"Schievink","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib138","unstructured":"NephroGenex. Pyridorin in Diabetic Nephropathy (PIONEER). NCT02156843. Bethesda, MD: US National Institutes of Health. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02156843; 2015 [accessed 07.29.15]"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib139","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib140","unstructured":"Bayer. Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02540993 U.S. National Institutes of Health; 2016 [accessed 03.21.15]"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib141","unstructured":"Eli Lilly. A study to test safety and efficacy of baricitinib in participants with diabetic kidney disease. NCT01683409. https:\/\/clinicaltrials.gov\/show\/NCT01683409; 2015 [accessed 03.03.15]."},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2016.08.001_bib142","doi-asserted-by":"crossref","first-page":"iii531","DOI":"10.1093\/ndt\/gfv195.01","article-title":"CCR2 inhibitor CCX140 effective in phase 2 clinical trial in diabetic nephropathy","volume":"30","author":"de Zeeuw","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2016.08.001_bib143","unstructured":"Concert. A phase 2 study to evaluate the safety and efficacy of CTP-499 in type 2 diabetic nephropathy patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01487109; 2015 [08.01.15]."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib144","unstructured":"Genkyotex. Safety and efficacy of oral GKT1377831 in patient with type 2 diabetes and albuminuria. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01487109; 2015 [accessed 08.01.15]."},{"key":"10.1016\/j.semnephrol.2016.08.001_bib145","series-title":"Genkyotex Fail. NOX inhibitor candidate doesn\u2019t follow through on phase II timeline","author":"Bancroft","year":"2015"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516300742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929516300742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T08:42:47Z","timestamp":1692607367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929516300742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":145,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0270929516300742"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.08.001","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing Treatments for Chronic Kidney Disease in the 21st Century","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2016.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}